Marine Compounds and Cancer: Where Do We Stand?
ExcerptIn Western countries, cancer is among the most frequent causes of death. Despite striking advances in cancer therapy, there is still an urgent need for new drugs in oncology. Current development favors so called “targeted agents” or drugs that target the immune system, i.e., therapeutic antibodies that enhance or facilitate an immune response against tumor cells (also referred to as “checkpoint inhibitors”). However, until recently, roughly 60% of drugs used in hematology and oncology were originally derived from natural sources, and one third of the top-selling agents are either natural agents or derivatives . There is justified hope for the discovery and development of new anticancer agents from the marine environment. Historically, this habitat has proven to be a rich source of potent natural compounds such as alkaloids, steroids, terpenes, macrolides, peptides, and polyketides, among others. Interestingly, marine agents and cancer treatment have had a special relationship from the beginning. One of the first marine-derived compounds, discovered in 1945 that was later developed into a clinically used drug, was spongothymidine [2–4], which was the lead compound for the discovery of cytarabine . Until today, cytarabine remains one of the most widely used agents in the treatment of acute myeloid leukemia and relapsed aggressive lymphomas. [...] View Full-Text
Share & Cite This Article
Dyshlovoy, S.A.; Honecker, F. Marine Compounds and Cancer: Where Do We Stand? Mar. Drugs 2015, 13, 5657-5665.
Dyshlovoy SA, Honecker F. Marine Compounds and Cancer: Where Do We Stand? Marine Drugs. 2015; 13(9):5657-5665.Chicago/Turabian Style
Dyshlovoy, Sergey A.; Honecker, Friedemann. 2015. "Marine Compounds and Cancer: Where Do We Stand?" Mar. Drugs 13, no. 9: 5657-5665.